Page 37 - MEMOCiberes014-ENG

demonstrated the role of specific extracellular matrix glycoproteins in fibroblast activity (fibroblast foci), such as tenascin-C, new fibrogenic pathways involved susceptible to being regulated and genetic aspects which can be regulated biologically (new anti-fibrotic approaches), which are reflected in references 10-26 .
Furthermore, the Pulmonary Fibrosis programme has worked on technology transfer and innovation, as a result of which collaboration and transfer agreements have been entered into with other CIBERS (CIBER- BBN, CIBERER; 2012 CIBERES-CIBERBBN-SEPAR project, workshop 2013 CIBERER-CIBERES), and with technology transfer and innovation enterprises; Advanced Medical Projects (AMP, Madrid, Spain), Histocell (Bilbao, Spain) and bVentura (Mollet del Vallés, Barcelona, Spain) . A patent on a new “medical device” in pulmonary fibrosis which is being evaluated has been drafted and filed (PCT/EP2015/050325) .
OTHER RESULTS OF THE FIBROSIS CRP:
• Guía Española para el diagnóstico y tratamiento de FPI: Xaubet A, Ancoche A J, Bollo E, et al ., Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis . Sociedad Española de Neumología y Cirugía Torácica (SEPAR) . Research Group on Diffuse Pulmonary Diseases . Arch Bronconeumol . August 2013; 49(8):343-53 .37 .
www.ciberes.org 37